Imagine your heart
in your hand.
Longevity is personal.
BioAI: Be well, uniquely.
One Drug. Different People.
The same medication can affect people differently. Genetics, age, organ function, other medications and lifestyle all influence how our bodies respond to treatment.
A dose that works well for one person may be ineffective or harmful for another.
Same dose, four individuals. Illustrative, not measured data.
Safer Medication. Healthier Aging.
As we age, medications often become more complex. Drug interactions, side effects and inappropriate dosing can contribute to avoidable harm.
Understanding individual drug responses could help support safer treatment and healthier aging.
- A Cholesterol medication
- B Blood thinner
- C Blood-pressure medication
- A + BInteraction flag
- A + CNo known issue
- B + CDose-dependent
Plus age, liver and kidney function.
- Elevated interaction risk flagged
- Dose sensitivity suggested by model
- Liver function worth monitoring
Illustrative example only. Not patient data, not a dosing suggestion, and not a clinical recommendation or decision-support service.
How BioAI Learns Human Drug Responses
Quris combines human tissue models, biological measurements and AI to study how drugs affect living human biology.
These experimental data help build the foundation for more personalized drug-safety prediction.
- 01
Human Tissue Models
- 02
Measured Drug Responses
- 03
Predictive AI
Imagine Testing a Drug on Your Own Cells.
Imagine testing a medication on living tissue created from your own cells—before taking it.
Quris is working toward a future where patient-specific biological models and AI could help guide safer, more personalized treatment decisions.
- 01
Individual
A person’s own cells
- 02
Cell Sample
Cells taken and cultured
- 03
Patient-Specific 3D Tissue
Living tissue built from them
- 04
Drug Response Assessment
How their tissue answers the drug
A development direction, not a current clinical service.
Explore the Future of Healthy Longevity
If you are working on healthy-aging research and want to explore whether human-relevant BioAI evidence fits your question, Quris welcomes the conversation.